ImmunityBio Investors Rally Behind Cancer Trial Milestone

ImmunityBio Inc. (NASDAQ:IBRX) shares are up during Thursday’s premarket session as the company has completed enrollment in its pivotal randomized trial evaluating Anktiva plus Bacillus Calmette-Guérin (BCG) against BCG alone for treating non-muscle invasive bladder cancer.85% Patients Maintain Complete ResponseThe trial, known as QUILT 2.005, has enrolled 366 patients ahead of schedule, with interim analysis indicating that 85% of those receiving Anktiva plus BCG maintained a complete response at six month ...